503b glp-1 FDA Proposes Ban on Bulk Compounding for Semaglutide, Tirzepatide, and Liraglutide FDA Enforcement - 503B GLP-1

Targeted screening of an anti-inflammatory polypeptide from Rhopilema esculentum Kishinouye cnidoblasts and elucidation of its mechanism in alleviating ulcerative colitis based on an analysis of the gut microbiota and metabolites

Journal of Pain Research , researchers looked at how common neuropathic pain is in the general U.S

Originally designed to manage diabetes, these medications have become increasingly popular for weight loss

Liver cirrhosis in glycogen storage disease Ib

This makes it a potential therapeutic option for conditions such as inflammatory bowel disease (IBD), peptic ulcers, and gastroesophageal reflux disease (GERD), where maintaining gut health is paramount for symptom management and overall well-being